



THE ATRIUM, SOUTHERN GATE, CHICHESTER, WEST SUSSEX P019 8SQ

*****IMMEDIATE RESPONSE REQUIRED*****

Your article may be published online via Wiley's EarlyView® service (<http://www.interscience.wiley.com/>) shortly after receipt of corrections. EarlyView® is Wiley's online publication of individual articles in full-text HTML and/or pdf format before release of the compiled print issue of the journal. Articles posted online in EarlyView® are peer-reviewed, copy-edited, author-corrected, and fully citable via the article DOI (for further information, visit www.doi.org). EarlyView® means you benefit from the best of two worlds - fast online availability as well as traditional, issue-based archiving.

Please follow these instructions to avoid delay of publication

READ PROOFS CAREFULLY

- This will be your only chance to review these proofs. **Please note that once your corrected article is posted online, it is considered legally published, and cannot be removed from the Web site for further corrections.**
- Please note that the volume and page numbers shown on the proofs are for position only.

ANSWER ALL QUERIES ON PROOFS (Queries for you to answer are attached as the last page of your proof.)

- List all corrections and send back via e-mail to the production contact as detailed in the covering e-mail, or mark all corrections directly on the proofs and send the scanned copy via e-mail. Please do not send corrections by fax or in the post.

CHECK FIGURES AND TABLES CAREFULLY

- Check size, numbering, and orientation of figures.
- All images in the PDF are downsampled (reduced to lower resolution and file size) to facilitate Internet delivery. These images will appear at higher resolution and sharpness in the printed article.
- Review figure legends to ensure that they are complete.
- Check all tables. Review layout, title, and footnotes.

COMPLETE CTA (if you have not already signed one)

- Please send a scanned copy with your proofs and post your completed original form to the address detailed in the covering e-mail. **We cannot publish your paper until we receive the original signed form.**

OFFPRINTS

- 25 complimentary offprints of your article will be dispatched on publication. Please ensure that the correspondence address on your proofs is correct for despatch of the offprints. If your delivery address has changed, please inform the production contact for the journal - details in the covering e-mail. Please allow six weeks for delivery.

Additional reprint and journal issue purchases

- Additional **paper reprints** (minimum quantity 100 copies) are available on publication to contributors. Quotations may be requested from mailto:author_reprints@wiley.co.uk. Orders for additional paper reprints may be placed in advance in order to ensure that they are fulfilled in a timely manner on publication of the article in question. Please note that offprints and reprints will be dispatched under separate cover.
- PDF files of individual articles may be purchased for personal use for \$25 via Wiley's Pay-Per-View service (see <http://www3.interscience.wiley.com/aboutus/ppv-articleselect.html>).
- Please note that regardless of the form in which they are acquired, reprints should not be resold, nor further disseminated in electronic or print form, nor deployed in part or in whole in any marketing, promotional or educational contexts without further discussion with Wiley. Permissions requests should be directed to <mailto:permreq@wiley.co.uk>
- Lead authors are cordially invited to remind their co-authors that the reprint opportunities detailed above are also available to them.
- If you wish to purchase print copies of the issue in which your article appears, please contact our Journals Fulfillment Department <mailto:cs-journals@wiley.co.uk> when you receive your complimentary offprints or when your article is published online in an issue. Please quote the Volume/Issue in which your article appears.

DETERMINANTS OF INVENTION COMMERCIALIZATION: AN EMPIRICAL EXAMINATION OF ACADEMICALLY SOURCED INVENTIONS

ATUL NERKAR^{1*} and SCOTT SHANE²

¹ Kenan-Flagler Business School, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.

² Department of Economics, Weatherhead School of Management, Case Western Reserve University, Cleveland, Ohio, U.S.A.

We examine the attributes of technological inventions that influence their commercialization. Using a unique dataset of the Massachusetts Institute of Technology (MIT)-licensed patents, we show that the likelihood of invention commercialization, which we measure by the achievement of first sale, is positively associated with two characteristics of licensed technological inventions—scope and pioneering nature—and has an inverted U-shaped relationship with the age of the invention. Copyright © 2007 John Wiley & Sons, Ltd.

1 INTRODUCTION

2
3 Past research in strategic management argues that
4 the ability to commercialize technological inven-
5 tions is an important driver of firm success (Cohen
6 and Levinthal, 1990; Eisenhardt and Martin, 2000;
7 Zahra and Nielsen, 2002). Thus, an important
8 strategic management question is: What explains
9 the differences in performance of firms at inven-
10 tion commercialization?

11 Much research has argued that this performance
12 is the result of firm capabilities (Dougherty and
13 Hardy, 1996; McGrath *et al.*, 1996; Pennings and
14 Harianto, 1992; Teece, 1986; Teece, Pisano, and

15
16 **Keywords:** technology; inventions; commercialization;
17 entrepreneurship

18 * Correspondence to: Atul Nerkar, Kenan-Flagler Business
19 School, University of North Carolina at Chapel Hill, CB #3490,
20 McColl 4068, Chapel Hill, NC 27599-3490, U.S.A.
21 E-mail: nerkar@unc.edu

23 Shuen, 1997), human resource practices (Nerkar, 24
25 McGrath, and MacMillan, 1996; Scott and Bruce, 26
27 1994), incentive structures (Nevens, Summe, and 28
29 Uttal, 1990; Teece, 1986), human capital of top 30
31 management teams (Bantel and Jackson, 1989; 31
32 Howell and Higgins, 1990) and the environment in 32
33 which firms operate (Abrahamson and Rosenkopf, 33
34 1993; David, 1988; Wade, 1996). While this litera- 34
35 ture has informed us greatly about the factors that 35
36 influence invention commercialization, it has, by 36
37 and large, neglected to discuss the effects of the 37
38 attributes of technological inventions themselves 38
39 (Henderson and Clark, 1990; Tushman and Ander- 39
40 son, 1986). 40

41 However, empirical examination of the effect 41
42 of the attributes of inventions on their subsequent 42
43 commercialization is important to strategic man- 43
44 agement research for several reasons. First, many 44
45 researchers have argued that the performance of 45
46 high-technology firms depends less on the strategic 46

1 choices of managers than on the effect of their
2 technology base and the network in which they
3 are located (Merges and Nelson, 1994; Podolny
4 and Stuart, 1995; Robinson, 1990; Rogers, 1982).

5 Second, some technologies are easier to com-
6 mercialize, more appropriable, and less risky than
7 other inventions, and therefore are more likely to
8 be commercialized (Colyvas *et al.*, 2002;
9 Gopalakrishna and Damanpour, 1994). Basic sci-
10 entific inventions, for instance, are seen as difficult
11 to appropriate and so are less likely than more
12 applied inventions to be commercialized (Arrow,
13 1962). Thus, consideration of the effect of the
14 attributes of technological inventions themselves
15 on their subsequent commercialization is important
16 to the development of an accurate understanding of
17 the performance of firms at invention commercial-
18 ization (McEvily and Chakravarthy, 2002).

19 Third, accurate testing of theories about the
20 effect of firm capabilities requires estimation of the
21 effect of the attributes of inventions on their com-
22 mercialization. Because researchers are unable to
23 conduct experiments on invention commercializa-
24 tion, they typically test theories about the effect
25 of firm capabilities through regression analysis.
26 For these regressions to yield accurate estimates,
27 researchers need to control for the effects of the
28 inventions themselves on the likelihood of com-
29 mercialization. By measuring the effects of differ-
30 ent dimensions of inventions on their likelihood
31 of commercialization, this study provides useful
32 information for future researchers to more pre-
33 cisely test theories regarding the effect of capa-
34 bilities on invention commercialization.

35 Lack of data is the main reason for our lack
36 of information on the effect of the attributes of
37 technical inventions on their commercialization.
38 To examine the effect of attributes of inventions
39 on their commercialization, researchers need to
40 gather data on the characteristics of a set of inven-
41 tions before the commercialization process occurs.
42 Unfortunately, most researchers lack access to
43 information about inventions at risk of commer-
44 cialization prior to the initiation of the commer-
45 cialization process. Therefore, they cannot address
46 questions about the effect of the characteristics of
47 inventions on their commercialization.

48 This study makes use of a unique dataset—the
49 population of 966 efforts by private firms to intro-
50 duce new products and services to the marketplace
51 using inventions assigned to the Massachusetts
52 Institute of Technology from 1980 to 1996 and

58 licensed to private firms—to overcome this prob- 58
59 lem of data access. Because a great deal of infor- 59
60 mation was collected on these inventions prior to 60
61 the efforts to commercialize them, and because 61
62 information is available on the outcomes of those 62
63 commercialization efforts, these data shed light on 63
64 the effect of the attributes of inventions on their 64
65 likelihood of commercialization. 65

66 We concentrate this article on those attributes 66
67 that enhance the appropriability of the returns to 67
68 innovation. The attributes of technological inven- 68
69 tions influence their likelihood of commercializa- 69
70 tion in so many different ways as to make the 70
71 study of all of them simultaneously empirically 71
72 intractable.¹ Moreover, the mechanisms underly- 72
73 ing the effect of most of these attributes on the 73
74 commercialization of inventions are largely unde- 74
75 veloped theoretically, rendering them unready for 75
76 empirical testing. 76

77 We focus our attention on the attributes of inven- 77
78 tions that affect the ability of firms to appropriate 78
79 returns from successful commercialization. This 79
80 focus was selected because appropriability is cen- 80
81 tral to the decisions of firms about invention com- 81
82 mercialization and because the arguments about 82
83 how the mechanism works are well enough devel- 83
84 oped in the theoretical literature to permit empir- 84
85 ical testing (Arrow, 1962; Cohen and Levinthal, 85
86 1989; Nelson, 1959). 86

87 THEORETICAL BACKGROUND AND 87 88 HYPOTHESES 88 89 89 90 90

91 To explain why the effect of the attributes of inven- 91
92 tions should influence their likelihood of com- 92
93 mercialization, we must first explain the nature 93
94 of invention commercialization and explain why 94
95 appropriability is important to motivating private 95
96 firms to engage in that process. The introduction 96
97 of a new product or service to the marketplace 97
98 is ‘a process that begins with an invention, pro- 98
99 ceeds with the development of the invention, and 99
100 results in the introduction of a new product, pro- 100
101 cess or service to the marketplace’ (Schumpeter, 101
102 102

103
104
105
106
107
108
109
110
111
112
113
114
115
¹ For example, Winter (1987) implies that the different attributes
of an invention, including the degree to which it is codified, part
of a system, and observable, affect its commercialization. Nelson
(1982) argues that the public–private dimension of inventions
influences their likelihood of commercialization. Malerba and
Orsenigo (1996) argue that the cumulativity of technology
underlying the development of technological inventions also
affects the likelihood of their commercialization.

1 1934: 66, 1950). This statement suggests that one
 2 important mechanism that affects the commercial-
 3 ization of an invention is the willingness of firms
 4 to ‘proceed with the development’ of an invention
 5 to transform it into a new product or service for
 6 introduction to the marketplace.

7 The willingness of firms to engage in the pro-
 8 cess of invention commercialization is influenced
 9 by expectations about the returns that they will
 10 capture from commercialization if they are suc-
 11 cessful. At least since Nelson (1959) and Arrow
 12 (1962), researchers have believed that private firms
 13 will not have an incentive to transform techno-
 14 logical inventions into commercial products and
 15 services unless they can appropriate the returns
 16 from commercialization. Therefore, those factors
 17 that increase the appropriability of the returns from
 18 invention commercialization lead firms to invest
 19 more heavily in that activity, and so increase
 20 the likelihood of commercialization (Levin *et al.*,
 21 1987).

22 Prior research indicates that at least three
 23 attributes of technological inventions influence the
 24 expectations of firms about the appropriability of
 25 the returns that would be earned from successful
 26 commercialization of the invention: the scope of
 27 the patent on the invention, the pioneering nature
 28 of the invention, and the age of the patent (Shane,
 29 2001).² As we explain more fully in the subsec-
 30 tions below, patent scope defines the breadth of
 31 intellectual property protection. Broader patents
 32 protect inventions against imitation from a wider
 33 range of potentially competing inventions than nar-
 34 rower patents (Merges and Nelson, 1990). The
 35 pioneering nature of the invention examines the
 36 degree to which the invention opens up new tech-
 37 nology domains. More pioneering inventions offer
 38 firms the possibility of learning curve and lead
 39 time advantages as well as broader property rights
 40 (Levin *et al.*, 1987; Ahuja and Lampert, 2001).
 41 Finally, the age of the invention examines the bal-
 42 ance between the passage of time necessary for the
 43 diffusion of an invention and the time remaining
 44 on patent protection. In the subsection below, we
 45 develop specific hypotheses about the relationship
 46 between these attributes of inventions and the per-
 47 formance of firms at invention commercialization.

48 _____
 49 ² Other attributes of patented technological inventions may also
 50 influence the expectations of firms about the appropriability
 51 of the returns that would be earned from successful commer-
 52 cialization of inventions; however, data limitations allow us to
 empirically examine only these three attributes.

Scope of the patent

The commercialization of technological inventions
 is highly uncertain (Zahra and Nielsen, 2002).
 Firms cannot know for sure whether they can
 create products or services from these inven-
 tions before trying. Inventions with broader scope
 of patent protection permit the appropriation of
 greater returns if commercialization is success-
 ful than inventions with narrower scope of patent
 protection (Merges and Nelson, 1990). Broader
 scope protection increases the likelihood that any
 trial-and-error efforts that are necessary to develop
 new products and services will result in something
 for which returns can be appropriated because
 broader patent scope allows the firm exploiting
 the invention to explore product and service appli-
 cations over a wider range of technical areas
 (March, 1991). Moreover, such trial-and-error pro-
 cesses can allow multiple successful applications
 to emerge from the same technological invention,
 which increases the potential returns that can be
 appropriated.

Furthermore, broader scope of patented inven-
 tions provides a wider range of alternative inven-
 tions that can be blocked by the patent, generating
 greater appropriability and increasing the value of
 the patented invention (Merges and Nelson, 1990).
 For instance, in the case of patented inventions
 belonging to biotechnology firms, Lerner (1995)
 shows that a one standard deviation increase in
 patent scope is associated with a 21 percent
 increase in firm valuation. Similarly, Shane (2001)
 shows that the greater the scope of a patent, the
 greater the likelihood of new firms being formed to
 try to commercialize the invention covered by the
 patent. These arguments lead to the first hypothe-
 sis:³

³ The broader the patent, the more incentive the firm has to bring
 to market an invention protected by it. The greater the incentive,
 the more resources the firm will put toward this commercial-
 ization effort and, consequently, the greater the likelihood of
 commercialization. This argument does not mean that there is no
 practical limit to the breadth of a patent. From a societal point of
 view, a patent can be too broad. Too broad patents deter nonhold-
 ers of the patent from inventing new technologies that would be
 blocked by the broadness of the patent. The patent office imposes
 a practical limit on the breadth of a patent. If the proposed patent
 is too broad, the patent office will not allow it. However, condi-
 tional on a patent having been issued by the patent office, which
 is what we examine empirically, the breadth of scope increases
 the likelihood of its commercialization. To confirm this argu-
 ment, we examined a regression model with a squared term for
 patent breadth and found that the results did prove statistically
 significant. Thus, the likelihood of commercialization is proven
 to increase with a broader-breadth patent.

54
 55
 56
 57

58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114

Hypothesis 1: All other things equal, the greater the scope of the invention's patent, the greater the likelihood of its commercialization.

Pioneering nature of invention

A second characteristic of an invention that we consider is its pioneering nature, or the degree to which the invention opens up new technology domains. We expect that the degree to which inventions are pioneering will increase the likelihood of commercialization because the pioneering nature increases the incentive of owners of the invention to invest time and money in its commercialization (Danneels and Kleinschmidt, 2001).

One of the primary reasons that firms try to commercialize inventions is to secure Schumpeterian rents that come from the creation of new products and services (Roberts, 1999; Winter, 1995). The use of technological inventions to create new products and services sometimes generates these rents by providing first mover (Lieberman and Montgomery, 1988) and learning curve advantages (Levin *et al.*, 1987).

Pioneering inventions are more likely than other inventions to provide first mover and learning curve advantages. The degree to which inventions draw on other inventions increases the likelihood that those inventions will be imitated (Ahuja and Lampert, 2001). Even when patented, inventions can be worked around, allowing others who have capabilities in an area to create similar products and processes (Nevens *et al.*, 1990). The more pioneering an invention is, the less available is the technology on which it builds. Hence, the more pioneering an invention, the lower the likelihood that it will be imitated.

Moreover, the breadth of property rights that the patent office assigns to inventions increases with the pioneering nature of inventions because less pioneering inventions must accommodate the property rights that have been given out to others already (Trajtenberg, 1990). This prior assignment of property rights reduces the appropriability of the returns to successful efforts to commercialize the inventions, and so makes firms more likely to pursue efforts to commercialize more pioneering inventions than less pioneering ones.⁴ These arguments lead to the second hypothesis:

⁴ However, inventions can be so novel that commercialization will be slow to occur, lessening the likelihood that firms will license them. The decision to license an invention depends on

Hypothesis 2: All other things equal, the more pioneering an invention, the greater the likelihood of its commercialization.

Age of the invention

Initially, as inventions age, the likelihood that they will be commercialized increases. In the beginning, technological inventions are nascent and considerable time and effort need to be invested in them before they can be transformed into commercially viable products and services (Jensen and Thursby, 2001). In addition, when inventions are new, their value is uncertain, leading them to be eschewed by potential adopters (Utterback, 1994). However, over time, the uncertainty about inventions is reduced, increasing information about their value, and hence the likelihood of their commercialization.

Ultimately the effect of invention age on the likelihood of commercialization turns negative. First, the returns from the commercialization of an invention that can be appropriated by a firm decline as the time remaining on a patent shrinks (Grabowski and Vernon, 1986). Second, the longer an invention has been around, the greater the possibility that substitutes for it will emerge (Agarwal and Gort, 2001). These substitutes reduce the returns that the firm can appropriate from commercializing the invention. These arguments lead to the third hypothesis:

Hypothesis 3: There is an inverted U-shaped relationship between the likelihood of commercialization of an invention and its age.

RESEARCH METHODOLOGY

Research site

We examine the effect of invention characteristics on the likelihood of their commercialization. Because the effects of invention characteristics on their commercialization are confounded with firm

the identification of a purpose for the invention by the licensee. Thus, firms will not license inventions if the need for products or services based on them is not there or if the real implication of the invention is not properly understood. Because our sample consists of inventions that have been licensed, the likelihood of commercialization increases with the pioneering nature of the invention.

1 capabilities at technological invention for inven- 58
 2 tions generated within firms, we examine exter- 59
 3 nally generated inventions that are then commer- 60
 4 cialized by firms. Universities provide the best 61
 5 source of inventions that are generated outside of, 62
 6 but commercialized by, firms (Henderson, Jaffe, 63
 7 and Trajtenberg, 1998). Therefore, we focus on the 64
 8 commercialization of university-generated inven- 65
 9 tions. Our specific source of externally generated 66
 10 inventions is the Massachusetts Institute of Tech- 67
 11 nology (MIT). 68

12
 13
 14 **Description of sample** 69

15
 16 Our unit of analysis is any effort made by a private 70
 17 firm to commercialize a patent assigned to MIT 71
 18 between 1980 and 1996 and licensed to a private 72
 19 firm. Thus, our sample consists of the population of 73
 20 all 966 licensing attempts by private-sector firms, 74
 21 assembled using data obtained from the records of 75
 22 the MIT Technology Licensing Office, the admin- 76
 23 istrative unit responsible for management of intel- 77
 24 lectual property assigned to MIT. 78

25 In general, the inventions that are licensed from 79
 26 MIT, and are found in our sample, are very 80
 27 early-stage inventions. Consistent with the work 81
 28 of other scholars who have examined this topic 82
 29 (e.g., Jensen and Thursby, 2001), the inventions 83
 30 are typically at the proof of principle or proof of 84
 31 concept stage, and are rarely prototypes that are 85
 32 ready for manufacture or production. For example, 86
 33 one invention in the sample is a ‘cross-flow filtra- 87
 34 tion molding method’ that is ‘particularly useful 88
 35 for forming complicated shapes from dispersions 89
 36 of particles in a liquid medium.’ Another invention 90
 37 is ‘a method for forming metal, ceramic or polymer 91
 38 compositions’ in which ‘fine-grain metal, ceramic 92
 39 or metal–ceramic or metal–polymer compositions 93
 40 are formed by impinging at least two liquid streams 94
 41 of metal, ceramic and/or polymer, upon each other 95
 42 to form a turbulent mixture having small eddies.’ 96

43 Because the inventions in the sample are very 97
 44 early-stage inventions that require additional devel- 98
 45 opment to reach the commercialization stage, this 99
 46 sample is appropriate for testing our hypotheses. 100
 47 To commercialize these inventions, firms must first 101
 48 engage in additional development that may or may 102
 49 not result in a commercial product. As a result, the 103
 50 effect of appropriability on the decision to develop 104
 51 technologies to commercialize them is salient in 105
 52 this setting. 106

Moreover, MIT patents provide a documented 58
 population of attempts by private-sector firms to 59
 commercialize inventions identified before commer- 60
 cialization efforts begin. As a result, we can 61
 avoid sampling on the dependent variable, a prob- 62
 lem that plagues many studies of invention com- 63
 mercialization efforts. 64

Furthermore, our focus is on understanding 65
 the characteristics of inventions themselves, as 66
 opposed to the environment or the capabilities of 67
 the firms that try to commercialize them. By focus- 68
 ing on attempts to license patented MIT inventions, 69
 we can examine a set of inventions for which we 70
 can obtain comparable characteristics of the inven- 71
 tions themselves. 72

73
 74
 75 **Analysis** 76

77 We use event history analysis to examine the 78
 79 probability that an attempt by a firm to com- 79
 80 mercialize an MIT invention leads to a first sale 80
 (Sorensen and Stuart, 2000). A spell begins when 81
 an MIT patent is licensed by a particular firm 82
 and continues until a first sale is reported. If a 83
 licensed patent does not lead to first sale, it is 84
 treated as censored. We use Cox regression mod- 85
 els to analyze the data, as we make no claims 86
 about the functional form of time dependence 87
 (Cox, 1972; Kalbfleisch and Prentice, 1980). The 88
 analysis incorporates both time-varying and time- 89
 invariant covariates. We cluster the standard errors 90
 on the number of licensing attempts to correct 91
 for the non-independence of the observations. The 92
 model specification is given below where $h(t)$, the 93
 hazard function, is the limit of the probability that 94
 a first sale event will occur between time t and 95
 $t + \nabla t$:• 96

$$h(t) = \lim \frac{\Pr\{t \leq T \leq t + C | T \geq t\}}{\nabla t}$$

$$= \exp\left\{\sum_{j=1}^n \beta_{ij} X_{ij}\right\}$$

101 The hazard function quantifies the instantaneous 101
 102 risk that a patent licensed from MIT will lead to 102
 103 first sale for the firm licensing it. The vector $\bullet X_{ij}$ 103
 104 represents the set of explanatory variables. 104

105
 106
 107 **Selection correction** 107

108 Commercialization of an MIT patent is not possi- 108
 109 ble if no one licenses the patent. This observation 109

1 is important because the probability that a patent
 2 is licensed may be influenced by the character-
 3 istics of the invention itself. For example, private
 4 firms may be more likely to license drug inventions
 5 than chemical, electrical, or mechanical inventions
 6 because of the historical success of universities at
 7 the commercialization of biotechnological inven-
 8 tions (Zucker and Darby, 1996). As a result, we
 9 need to provide a selection correction for those
 10 inventions that are licensed by firms. We create
 11 such a variable, using Lee's (1983) generalization
 12 of the Heckman selection model. This control vari-
 13 able makes the estimates of our predictor variables
 14 more precise by mitigating the effects of omitted
 15 variable bias (Greene, 2000). To create our selec-
 16 tion correction variable, we use a Cox regression
 17 model that predicts the hazard of the license for all
 18 1397 MIT inventions patented between 1980 and
 19 1996 to generate our selection correction variable,
 20 λ :

$$\lambda_{it} = \frac{\phi[\Phi^{-1}(F_i(t))]}{1 - F_i(t)}$$

24 where $F_i(t)$ is the cumulative hazard function for
 25 project i at time t , ϕ is the standard normal density
 26 function, and Φ^{-1} the inverse of the standard
 27 normal distribution function (Lee, 1983).

28 An effective selection correction variable
 29 requires at least one variable that should influ-
 30 ence the likelihood of licensing, but not com-
 31 mercialization of the invention. We include the
 32 source of funding for the invention (e.g., govern-
 33 ment funded, industry funded) as a covariate in
 34 the regression to predict licensing. Firms should
 35 be more likely to license industry-funded research
 36 because firms tend to obtain a right of first refusal
 37 to license inventions that are derived from research
 38 that they support. is then included as a variable
 39 in the Cox regressions to predict commercializa-
 40 tion.

43 Measurement

44 Dependent variable

- 47 • *Commercialization of the invention.* We opera-
 48 tionalize the dependent variable, invention com-
 49 mercialization, as the achievement of first sale of
 50 a product or service that makes use of the inven-
 51 tion. We measure this variable as the receipt
 52 of the first dollar of revenue by the licensing

firm. While our measure does not necessarily
 represent 'commercial success' because many
 firms that achieve first sale for their new prod-
 ucts or services fail to generate much profit from
 those products or services, this measure is nev-
 ertheless something important to predict. The
 achievement of first sale is a necessary condition
 for commercial success because firms cannot
 generate profit from products and services that
 never reach first sale (King and Tucci, 2002;
 Mitchell and Singh, 1996; Zahra and Nielsen,
 2002).

Independent variables

- *Invention patent scope.* Following
 Lerner (1995), we measure this variable as the
 number of international patent classes that a
 patent has on its front page.
- *Pioneering nature of the invention.* Following
 Ahuja and Lampert (2001), who use the lack
 of prior art to measure the pioneering nature of
 inventions created by firms, we measure it as the
 number of prior patents referenced by a patent.
- *Age of the invention.* This is measured as time
 elapsed in years since the patent was granted.

Control variables

- *Technical fields.* We control for the techni-
 cal field in which the licensed invention is
 found—chemical, drug, electrical, mechanical
 (•other is the base case)—because the rate
 of invention commercialization differs across
 technical fields. The existence of technologi-
 cal opportunities, the resource requirements and
 time needed to commercialize inventions, the
 tendency of inventors to disclose their inven-
 tions, and other factors all vary across technical
 fields (Cohen and Levinthal, 1989). By control-
 ling for the technical field, we can partial out
 this type of variation from the data.
- *Year.* We control for the time period when the
 patent was filed because of a variety of changes
 to university technology licensing during the
 1980–96 period.
- *Number of licensees.* This variable controls for
 the number of licensees to each patent. The abil-
 ity to commercialize inventions could spill over

from one licensee to another. Moreover, a variety of different approaches to commercialization efforts could enhance the pace of commercialization. Therefore, accurate estimation of the effects of our independent variables on commercialization requires controlling for the number of entities seeking to commercialize each patent at a given point in time.

- *Exclusivity of invention.* Because we posit that the appropriability of an invention affects the likelihood of commercialization, it is important for us to control for the effect of the licensing agreement. If the sourced invention is also available to other firms, or is part of the public domain, incentives to commercialize can be undermined (Narin, Hamilton, and Olivastro, 1997). Based on MIT records, we classify each licensed patent as to whether it was licensed exclusively in a field of use. This variable is a dummy variable and is coded 1 when the license is exclusive and 0 when it is not. Readers should note that there can be multiple licensees to an exclusively licensed patent because exclusivity can include exclusivity in a field of use. In that case, the multiple licensees are exploiting the inventions in different fields of use.
- *Firm experience.* As mentioned earlier, one of

the factors that explain differences in performance of invention commercialization is firm capability. We control for firm effects by including a variable that measures the prior experience of the licensing firms at commercializing MIT inventions. Based on MIT's records, we include a variable that measures the number of MIT patents licensed by the firm prior to the focal patent. This variable is skewed and we use a logarithmic transformation to normalize it.

- *Start-up firm.* New firms are more likely than existing firms to suffer from liabilities of newness, absence of capabilities, and lack of legitimacy, which make them less likely to commercialize inventions. Therefore, we control for start-up firms with a dummy variable of 1 if the records of the MIT Technology Licensing Office indicate that the licensee was a firm that did not exist prior to the year of the license.

RESULTS

The descriptive statistics are reported in Table 1 along with the correlation matrix. The highest correlation between any two independent variables is $r = 0.45$ between the log of firm experience and year. This level of correlation indicates that there

Table 1. Descriptive statistics and correlation matrix ($N = 3581$)

	Mean	S.D.	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
Scope of invention (1)	1.38	0.69	1.00											
Pioneering nature of invention (2)	7.55	9.72	-0.05	1.00										
Industry-funded invention (3)	0.17	0.37	0.04	0.02	1.00									
Drug (4)	0.29	0.45	0.14	-0.30	-0.07	1.00								
Chemical (5)	0.30	0.46	0.00	-0.05	-0.02	-0.41	1.00							
Electrical (6)	0.25	0.43	-0.02	0.04	0.04	-0.37	-0.38	1.00						
Mechanical (7)	0.03	0.18	-0.06	0.01	0.14	-0.12	-0.12	-0.11	1.00					
Number of licensees (8)	2.05	1.78	0.09	-0.01	-0.09	0.01	0.06	0.02	-0.08	1.00				
Age of invention (9)	6.63	4.21	0.00	-0.14	-0.14	0.07	0.02	-0.06	-0.01	0.20	1.00			
Year (10)	•1992	3.59	0.04	0.23	0.13	-0.20	0.02	0.14	-0.02	0.20	0.26	1.00		
Firm experience (11)	1.90	1.27	-0.09	-0.08	-0.05	0.15	0.02	-0.13	-0.01	0.04	0.45	0.22	1.00	
Start-up (12)	0.32	0.47	-0.02	0.02	-0.05	-0.06	0.01	0.00	-0.02	-0.11	0.08	-0.02	-0.00	1.00
Exclusive (13)	0.80	0.40	-0.09	0.11	-0.00	0.01	-0.01	-0.10	0.02	-0.06	-0.19	0.08	0.01	0.02

All correlation coefficients above 0.05 are significant at $p < 0.05$.

1 is little likelihood of multicollinearity influencing
2 the validity and generalizability of our results.

3 Table 2 reports the results of the Cox propor-
4 tional hazard regression analysis of the charac-
5 teristics of inventions on the likelihood of first
6 sale. In sum, all three hypotheses were sup-
7 ported. In Table 2, the likelihood of first sale is
8 the dependent variable as described above. The
9 first model reports the baseline where techni-
10 cal field (chemical, drug, electrical, mechanical),
11 year, and other controls were included. The over-
12 all model is significant ($\chi^2 = 58.80$, $p < 0.0001$).
13 In Model 2, the scope variable is added. Mod-
14 els 3 and 4 introduce the independent effects of
15 pioneering nature and age, respectively. Model
16
17
18

5 is the full model, which includes all vari- 19
ables. 20

In Hypothesis 1, we proposed that inventions 21
with broader patent scope were more likely to 22
reach first sale than inventions with narrower 23
patent scope. Model 2 presents evidence with 24
respect to this hypothesis. The overall model is sig- 25
nificant ($\chi^2 = 74.08$, $p < 0.0001$). The coefficient 26
for the scope variable is positive and significant 27
($\beta = 0.2914$, $p < 0.0001$). 28
29

Hypothesis 2 proposed that the pioneering nature 30
of the invention would positively influence the 31
likelihood of first sale. This hypothesis is sup- 32
ported. Model 4 is significant ($\chi^2 = 74.49$, $p <$ 33
0.0001). The effect of pioneering nature (which is 34
35
36

Table 2. Cox regression to predict the hazard of first sale

	Model 1	Model 2	Model 3	Model 4	Model 5
Scope of invention	#	0.2914**** (0.0798)	#	#	0.2969**** (0.0790)
Pioneering nature	#	#	-0.0261* (0.0112)	#	-0.0270* (0.0117)
Age of invention	#	#	#	0.1355* (0.0617)	0.1328* (0.0612)
Age \times Age	#	#	#	-0.0083* (0.0037)	-0.0084* (0.0037)
λ	-0.1584 (0.1421)	-0.2005 (0.1413)	0.0530 (0.1643)	-0.1666 (0.1419)	0.0002 (0.1645)
Drug	0.2744 (0.2764)	0.1612 (0.2724)	-0.1588 (0.3451)	0.2683 (0.2761)	-0.2800 (0.3382)
Chemical	0.5312 [†] (0.2747)	0.4061 (0.2765)	0.4145 (0.2780)	0.5657* (0.2753)	0.3228 (0.2786)
Electrical	0.1543 (0.3190)	0.1515 (0.3206)	0.1315 (0.3084)	0.1866 (0.3201)	0.0582 (0.3132)
Mechanical	-0.2800 (0.6570)	-0.3456 (0.6735)	-0.3103 (0.6512)	-0.1948 (0.6605)	-0.3017 (0.6739)
Exclusivity	0.4019 [†] (0.2114)	0.4631* (0.2148)	0.3955 [†] (0.2113)	0.3796 [†] (0.2117)	0.4287* (0.2151)
Number of licensees	0.1333**** (0.0347)	0.1307**** (0.0342)	0.1234**** (0.0345)	0.1271**** (0.0355)	0.1161**** (0.0347)
Firm experience	0.0256**** (0.0047)	0.0284**** (0.0045)	0.0258**** (0.0047)	0.0258**** (0.0049)	0.0291**** (0.0046)
Start-up firm	0.0636 (0.1502)	0.0707 (0.1495)	0.0762 (0.1502)	0.0809 (0.1546)	0.1076 (0.1538)
Year	0.0038 (0.0251)	-0.0015 (0.0252)	0.0091 (0.0250)	0.0042 (0.0256)	0.0047 (0.0258)
Number of observations	3581	3581	3581	3581	3581
Number of licensing attempts	966	966	966	966	966
Number of events	197	197	197	197	197
Log-likelihood	-1201.24	-1197.14	-1198.80	-1198.95	-1192.23
χ^2 model	58.80****	74.08****	74.49****	67.82****	99.31****

Significant at: **** $p < 0.0001$ level; *** $p < 0.001$ level; ** $p < 0.01$ level; * $p < 0.05$ level; [†] $p < 0.10$ level.

#, variable not included in the regression.

Robust standard errors in parentheses, clustering on licensing attempts.

1 coded inversely) in Model 3 in Table 2 is signifi-
 2 cant and negative ($\beta = -0.0261$, $p < 0.05$).

3 In Hypothesis 3 we predicted that age of innova-
 4 tions would have an inverted U-shaped relationship
 5 with likelihood of first sale. Overall, Model 4 is
 6 significant ($\chi^2 = 67.82$, $p < 0.0001$). The coef-
 7 ficients of the single term and the squared term
 8 are significant and in the hypothesized directions
 9 ($\beta_{\text{age}} = 0.155281$, $p < 0.05$; $\beta_{\text{agesquared}} = -0.0083$,
 10 $p < 0.05$). The point of inflection at which the
 11 association between likelihood of first sale and age
 12 of innovation turns negative is 7.9 years and is
 13 within the range of the data.

14 The full model with all the explanatory vari-
 15 ables and controls is presented as Model 5. The
 16 hypotheses continue to be supported; the coef-
 17 ficients are significant and in the hypothesized
 18 direction, while the overall model is also sig-
 19 nificant ($\chi^2 = 99.31$, $p < 0.0001$). The relative
 20 strengths of each of the independent variables
 21 in the full model can be examined by keeping
 22 each variable at its mean level, while examin-
 23 ing the increase in the focal variable. Thus, an
 24 increase of one international patent class (our mea-
 25 sure of scope) increases the hazard of first sale
 26 by 34.5 percent, while each prior citation on a
 27 patent (our measure of the lack of pioneering
 28 nature) leads to a reduction in the hazard of first
 29 sale by 2.7 percent. Similarly, an increase of one
 30 year in the age of invention from its average
 31 increases the hazard of first sale by 14.2 percent
 32 until the patent reaches 7.9 years of age, at which
 33 time each one-year increase in the age of the
 34 patent decreases the hazard of first sale by 1 per-
 35 cent.

36 Readers should note that the selection correc-
 37 tion for the hazard of licensing is insignificant in
 38 the main regression analyses and does not influ-
 39 ence the magnitude of the effects of scope, age,
 40 or pioneering nature on the likelihood of inven-
 41 tion commercialization. Because the lambda for
 42 licensing is insignificant in our main regressions,
 43 we examined the effect of scope, age, and pio-
 44 neering nature without correcting for the haz-
 45 ard of licensing in unreported regressions. This
 46 alternative analysis allows us to relax assump-
 47 tions about the form of the relationship between
 48 the error terms in the selection and second-stage
 49 equations. We find qualitatively the same results
 50 for our predictor variables under this alternative
 51 specification. Thus, we can also say that, condi-
 52 tional on an invention being licensed, the effects

of scope, age, and pioneering nature on the likeli- 58
 hood of commercialization are as we had hypoth- 59
 esized. 60

61
 62
DISCUSSION 63

This article examined the effect of three character- 65
 istics of inventions that affect the degree to which 66
 firms can appropriate the returns from their com- 67
 mercialization on the likelihood that those inven- 68
 tions achieve first sale. Using a unique dataset of 69
 all 966 attempts by private sector firms to com- 70
 mercialize inventions licensed from MIT between 71
 1980 and 1996, we showed that scope, pioneering 72
 nature, and age of inventions influence the likeli- 73
 hood of their commercialization. 74

75
Implications 76

The results of this study have several implica- 78
 tions for research on technology strategy. First, 79
 our effort provides empirical evidence that the 80
 characteristics of technological inventions, which 81
 theory suggests should increase the appropriability 82
 of returns from the introduction of new products 83
 and services (e.g., Arrow, 1962; Nelson, 1959), 84
 do affect the likelihood that firms commercialize 85
 inventions. 86

Second, our effort reminds researchers of the 87
 importance of considering the effect of the nature 88
 of technological inventions themselves, rather than 89
 just firm capabilities, on the commercialization of 90
 inventions. While research in strategic manage- 91
 ment offers empirical support for the argument 92
 that commercialization capabilities influence per- 93
 formance at technology commercialization, this 94
 research often loses sight of the fact that inven- 95
 tions themselves are unique and influence perfor- 96
 mance at technology commercialization through 97
 the incentives that they provide to firms. It is 98
 important to tease apart the effects of firm capabil- 99
 ities and the effects of the characteristics of inven- 100
 tions in order to gain an accurate understanding of 101
 invention commercialization. 102

Because we explore efforts by private sector 103
 firms to commercialize patented inventions from 104
 a single university, we examine data in which the 105
 effects of the invention attributes on commercial- 106
 ization efforts were independent of the university's 107
 effort to develop the inventions. Thus, we iso- 108
 late the effect of invention characteristics on the 109

1 post-invention commercialization efforts of private
2 sector firms, and show that invention attributes that
3 affect the appropriability of the returns to commer-
4 cialized inventions influence those commercializa-
5 tion efforts.

6 Third, our study provides a useful methodologi-
7 cal tool for researchers interested in examining the
8 effect of firm characteristics on the commercializa-
9 tion of inventions. Accurate testing of many theo-
10 ries of firm performance (for technology-intensive
11 firms) requires estimation of the effect of the
12 attributes of inventions (such as the ones we use in
13 this research) on their commercialization. By mea-
14 suring the effects of different dimensions of inven-
15 tions on their likelihood of commercialization, our
16 study provides useful information about accurately
17 controlling for the characteristics of inventions that
18 future researchers can use to test theories of firm
19 performance more precisely. For instance, future
20 research examining differences in the commercial-
21 ization capabilities of firms on their performance
22 at invention commercialization need to control for
23 the dimensions of inventions that we have found
24 to affect commercialization—scope, pioneering
25 nature, and age of invention—to obtain accurate
26 estimates of the effect of capabilities on perfor-
27 mance, given the possible correlation between firm
28 capabilities and invention characteristics.

29 Fourth, our results provide insight into strategic
30 efforts by firms to source inventions from outside
31 organizational boundaries. Previous research has
32 shown that external sourcing is important to many
33 firms, which obtain access to new technologies to
34 enhance their performance (Chesbrough and Teece,
35 1996; Cohen and Levinthal, 1990; Tripsas, 1997).
36 However, the literature offers little guidance about
37 what externally sourced inventions are more likely
38 to be commercialized than others. Our results
39 show that, all other things being equal, externally
40 sourced inventions that have broad scope, are pio-
41 neering, and are of average age are more likely to
42 be commercialized than other externally sourced
43 inventions. While managers would need to bal-
44 ance these attributes against other factors, such as
45 cost and risk, in making decisions about which
46 inventions to source externally, these results offer
47 insight consistent with other research (Jensen and
48 Thursby, 2001) about which externally sourced
49 inventions firms should select.

Limitations

To overcome the confounding relationship between
firm capabilities and invention characteristics
present with inventions that are developed within
firms, we examined the commercialization of exter-
nally generated inventions. This approach limits
our ability to generalize our findings to internally
created inventions. However, we believe that this
trade-off is worthwhile because the commercializa-
tion of externally generated inventions is, in and
of itself, a phenomenon of significant importance
to firms (Chesbrough and Teece, 1996; Cohen and
Levinthal, 1990; Tripsas, 1997).

The generalizability of our results is also lim-
ited by the representativeness of MIT inventions.
On average, university inventions are more impor-
tant and more general than private sector inven-
tions (Henderson *et al.*, 1998). Moreover, MIT's
inventions may have more commercial potential
than inventions from other academic institutions
because of the research prowess of the institution
and its closeness to industry. Future research that
examines a broader set of externally sourced inven-
tions is necessary to show the generalizability of
our findings to other sources of invention.

While our analysis supports our hypotheses,
other variables may also influence the commer-
cialization of MIT-licensed inventions. We control
for firm effects by including the past experience
of the firm in licensing from MIT, but this is
a crude proxy. If correlations exist between the
invention characteristics we examine and unob-
served attributes of licensees, our coefficients will
be overstated. Future research that controls for
more firm characteristics can improve the preci-
sion of our estimates of the effect of invention
characteristics on their commercialization.

Our study predicts the likelihood of invention
commercialization, not 'successful' commercial-
ization. We focused on the likelihood of com-
mercialization because researchers disagree about
how to define 'success' at commercialization, but
recognize that the achievement of first sale is a
necessary condition for all measures of 'success'
(King and Tucci, 2002; Zahra and Nielsen, 2002).

The factors that this study showed to predict
the likelihood of commercialization may not pre-
dict many things that researchers define as 'suc-
cess' at commercialization. For instance, some
researchers (Nerkar and Roberts, 2004) have con-
sidered 'successful' commercialization to be the

58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114

1 achievement of a certain level of sales for a number
 2 of years. Other researchers have considered ‘suc-
 3 cessful’ commercialization to be a high number of
 4 new product introductions (Katila, 2002). Future
 5 research that examines the effect of the attributes
 6 of inventions on the achievement of these and other
 7 measures of ‘success’ would be necessary before
 8 researchers could say that the attributes of inven-
 9 tions that we examined explain anything more than
 10 the likelihood of invention commercialization. It is
 11 possible that additional research would show that
 12 that the attributes of the inventions that we mea-
 13 sured do not predict these different measures of
 14 ‘successful’ commercialization.

15 Despite these limitations, this paper shows that
 16 the likelihood of invention commercialization is
 17 positively associated with two characteristics of
 18 licensed technological inventions—scope and pio-
 19 neering nature—and has an inverted U-shaped
 20 relationship with the age of the invention. These
 21 findings have important implications for firms that
 22 source technological inventions externally.

23
 24 **REFERENCES**

25
 26 Abrahamson E, Rosenkopf L. 1993. Institutional and
 27 competitive bandwagons: using mathematical-
 28 modeling as a tool to explore innovation diffusion.
 29 *Academy of Management Review* **18**(3): 487–517.
 30 Agarwal R, Gort M. 2001. First-mover advantage and the
 31 speed of competitive entry, 1887–1986. *Journal of*
 32 *Law and Economics* **44**(1): 161–178.
 33 Ahuja G, Lampert CM. 2001. Entrepreneurship in the
 34 large corporation: a longitudinal study of how
 35 established firms create breakthrough inventions.
 36 *Strategic Management Journal*, June–July Special
 37 Issue **22**: 521–543.
 38 Arrow KJ. 1962. Economics of welfare and the allocation
 39 of resources for invention. In *The Rate and*
 40 *Direction of Inventive Activity: Economic and social*
 41 *factors*, Nelson RR (ed). Princeton University Press:
 42 Princeton, NJ; 165–180.
 43 Bantel KA, Jackson SE. 1989. Top management and
 44 innovations in banking: does the composition of the
 45 top team make a difference? *Strategic Management*
 46 *Journal*, Summer Special Issue **10**: 107–124.
 47 Chesbrough HW, Teece DJ. 1996. When is virtual
 48 virtuous? Organizing for innovation. *Harvard Business*
 49 *Review* **74**(1): 65–73.
 50 Cohen WM, Levinthal DA. 1989. Innovation and learn-
 51 ing: the two faces of R&D. *Economic Journal*
 52 **99**(397): 569–596.
 53 Cohen WM, Levinthal DA. 1990. Absorptive-capacity:
 54 a new perspective on learning and innovation.
 55 *Administrative Science Quarterly* **35**(1): 128–152.
 56 Colyvas J, Crow M, Gelijns A, Mazzoleni R, Nel-
 57 son RR, Rosenberg N, Sampat BN. 2002. How do

university inventions get into practice? *Management*
Science **48**(1): 61–72. 58
 59
 Cox DR. 1972. Regression models and life-tables. 60
Journal of the Royal Statistical Society **B34**(2):
 187–220. 61
 62
 Danneels E, Kleinschmidt EJ. 2001. Product innovative-
 63 ness from the firm’s perspective: its dimensions and
 64 their relation with project selection and performance.
Journal of Product Innovation Management **18**(6):
 357–373. 65
 66
 David PA. 1988. Path dependence: putting the past into
 67 the future of economics. Working paper, Stanford
 University, Stanford, CA. 68
 69
 Dougherty D, Hardy C. 1996. Sustained product inno-
 70 vation in large, mature organizations: overcom-
 71 ing innovation-to-organization problems. *Academy of*
Management Journal **39**(5): 1120–1153. 72
 73
 Eisenhardt KM, Martin JA. 2000. Dynamic capabilities:
 74 what are they? *Strategic Management Journal*,
 October–November Special Issue **21**: 1105–1121. 75
 76
 Gopalakrishna S, Damanpour F. 1994. Patterns of gen-
 77 eration and adoption of innovation in organizations:
 78 contingency models of innovation attributes. *Journal*
of Engineering and Technology Management **11**(2):
 95–117. 79
 80
 Grabowski H, Vernon J. 1986. Longer patents for lower
 81 imitation barriers: the 1984 Drug Act. *American*
Economic Review **76**(2): 195–199. 82
 83
 Greene W. 2000. *Econometric Analysis*. Prentice-Hall:
 Upper Saddle River, NJ. 84
 85
 Henderson RM, Clark KB. 1990. Architectural innova-
 86 tion: the reconfiguration of existing product technolo-
 87 gies and the failure of established firms. *Administrative*
Science Quarterly **35**(1): 9–30. 88
 89
 Henderson RM, Jaffe A, Trajtenberg M. 1998. Universi-
 90 ties as a source of commercial technology: a detailed
 91 analysis of university patenting, 1965–1988. *Review*
of Economics and Statistics **80**(1): 119–127. 92
 93
 Howell JM, Higgins CA. 1990. Champions of techno-
 94 logical innovation. *Administrative Science Quarterly*
35(2): 317–341. 95
 96
 Jensen R, Thursby M. 2001. Proofs and prototypes
 97 for sale: the tale of university licensing. *American*
Economic Review **91**(1): 240–260. 98
 99
 Kalbfleisch JD, Prentice RL. 1980. *The Statistical*
Analysis of Failure Time Data. Wiley: New York. 100
 101
 Katila R. 2002. New product search overtime: past ideas
 102 in their prime? *Academy of Management Journal*
45(5): 995–1010. 103
 104
 King AA, Tucci CL. 2002. Incumbent entry into new
 105 market niches: the roles of experience and managerial
 106 choice in the creation of dynamic capabilities.
Management Science **48**(2): 171–186. 107
 108
 Lee L. 1983. Generalized econometric models with
 109 selectivity. *Econometrica* **51**: 507–512. 110
 111
 Lerner J. 1995. Patenting in the shadow of competitors.
Journal of Law and Economics **38**: 463–495. 112
 113
 Levin RC, Klevorick AK, Nelson RR, Winter SG. 1987.
 114 Appropriating the returns from industrial research and
 development. *Brookings Papers on Economic Activity*
1987(3): 783–831. 115

- 1 Lieberman MB, Montgomery DB. 1988. First-mover
2 advantages. *Strategic Management Journal*, Summer
3 Special Issue **9**: 41–58.
- 4 Malerba F, Orsenigo L. 1996. Schumpeterian patterns of
5 innovation are technology-specific. *Research Policy*
6 **25**(3): 451–478.
- 7 March JG. 1991. Exploration and exploitation in
8 organizational learning. *Organization Science* **2**(1):
9 71–87.
- 10 McEvily SK, Chakravarthy B. 2002. The persistence of
11 knowledge-based advantage: an empirical test for
12 product performance and technological knowledge.
13 *Strategic Management Journal* **23**(4): 285–305.
- 14 McGrath RG, Tsai M-H, Venkataraman S, MacMil-
15 lan IC. 1996. Innovation, competitive advantage, and
16 rent: a model and test. *Management Science* **42**(3):
17 389–403.
- 18 Merges RP, Nelson RR. 1990. On the complex eco-
19 nomics of patent scope. *Columbia Law Review* **90**(4):
20 839–916.
- 21 Merges RP, Nelson RR. 1994. On limiting or encourag-
22 ing rivalry in technical progress: the effect of patent
23 scope decisions. *Journal of Economic Behavior and*
24 *Organization* **25**(1): 1–24.
- 25 Mitchell W, Singh K. 1996. Survival of businesses
26 using collaborative relationships to commercialize
27 complex goods. *Strategic Management Journal* **17**(3):
28 169–195.
- 29 Narin F, Hamilton KS, Olivastro D. 1997. The increasing
30 linkage between U.S. technology and public science.
31 *Research Policy* **26**(3): 317–330.
- 32 Nelson RR. 1959. The simple economics of basic
33 scientific research. *Journal of Political Economy*
34 **67**(3): 297–306.
- 35 Nelson RR. 1982. The role of knowledge in R&D
36 efficiency. *Quarterly Journal of Economics* **97**(2):
37 453–470.
- 38 Nerkar A, Roberts PW. 2004. Technological and product-
39 market experience and the success of new product
40 introductions in the pharmaceutical industry. *Strategic*
41 *Management Journal*, August–September Special
42 Issue **25**: 779–799.
- 43 Nerkar AA, McGrath RG, MacMillan IC. 1996. Three
44 facets of satisfaction and their influence on the
45 performance of innovation teams. *Journal of Business*
46 *Venturing* **11**(3): 167–188.
- 47 Nevens MT, Summe GL, Uttal B. 1990. Commercializ-
48 ing technology: what the best companies do. *Harvard*
49 *Business Review* **68**(3): 154–164.
- 50 Pennings JM, Harianto F. 1992. Technological network-
51 ing and innovation implementation. *Organization Sci-*
52 *ence* **3**(3): 356–382.
- 53 Podolny JM, Stuart TE. 1995. A role-based ecology of
54 technological change. *American Journal of Sociology*
55 **100**(5): 1224–1260.
- 56 Roberts PW. 1999. Product innovation, product-market
57 competition and persistent profitability in the
58 U.S. pharmaceutical industry. *Strategic Management*
59 *Journal* **20**(7): 655–670.
- 60 Robinson WT. 1990. Product innovation and start-up
61 business market share performance. *Management*
62 *Science* **36**(10): 1279–1289.
- 63 Rogers EM. 1982. *Diffusion of Innovations* (3rd edn).
64 Free Press: New York.
- 65 Schumpeter JA. 1934. *The Theory of Economic Develop-*
66 *ment: An Inquiry Into Profits, Capital, Credit, Inter-*
67 *est, and the Business Cycle*. Harvard University Press:
68 Cambridge, MA.
- 69 Schumpeter JA. 1950. *Capitalism, Socialism, and Democ-*
70 *racy* (3d edn). Harper & Row: New York.
- 71 Scott SG, Bruce RA. 1994. Determinants of innovative
72 behavior: a path model of individual innovation in the
73 workplace. *Academy of Management Journal* **37**(3):
74 580–607.
- 75 Shane S. 2001. Technological opportunities and new firm
76 creation. *Management Science* **47**(2): 205–220.
- 77 Sorensen JB, Stuart TE. 2000. Aging, obsolescence, and
78 innovation. *Administrative Science Quarterly* **45**(1):
79 81–112.
- 80 Teece DJ. 1986. Profiting from technological innovation:
81 implications for integration, collaboration, licensing
82 and public policy. *Research Policy* **15**(6): 285–305.
- 83 Teece DJ, Pisano G, Shuen A. 1997. Dynamic capabili-
84 ties and strategic management. *Strategic Management*
85 *Journal* **18**(7): 509–533.
- 86 Trajtenberg M. 1990. A penny for your quotes: patent
87 citations and the value of innovations. *Rand Journal*
88 *of Economics* **21**(1): 172–188.
- 89 Tripsas M. 1997. Unraveling the process of creative
90 destruction: complementary assets and incumbent sur-
91 vival in the typesetter industry. *Strategic Management*
92 *Journal*, Summer Special Issue **18**: 119–142.
- 93 Tushman ML, Anderson PC. 1986. Technological discon-
94 tinuities and organizational environments. *Administra-*
95 *tive Science Quarterly* **31**(3): 439–465.
- 96 Utterback J. 1994. *Mastering the Dynamics of Innovation*.
97 Harvard Business School Press: Boston, MA.
- 98 Wade J. 1996. A community-level analysis of sources and
99 rates of technological variation in the microprocessor
100 market. *Academy of Management Journal* **39**(5):
101 1218–1244.
- 102 Winter SG. 1987. Knowledge and competence as
103 strategic assets. In *The Competitive Challenge: Strategies*
104 *for Industrial Innovation and Renewal*, Teece DJ (ed).
105 Ballinger: Cambridge, MA; 186–219.
- 106 Winter SG. 1995. Four r's of profitability: rents,
107 resources, routines and replication. In *Evolutionary and*
108 *Resource based Views: A Synthesis*, Montgomery C (ed).
109 Kluwer Academic: Amsterdam;
110 147–178.
- 111 Zahra SA, Nielsen AP. 2002. Sources of capabilities,
112 integration and technology commercialization. *Strate-*
113 *gic Management Journal* **23**(5): 377–398.
- 114 Zucker LG, Darby MR. 1996. Star scientists and
115 institutional transformation: patterns of invention and
116 innovation in the formation of the biotechnology
117 industry. *Proceedings of the National Academy of*
118 *Science* **93**: (November): 12709–12712.

1		58
2	QUERIES TO BE ANSWERED BY AUTHOR	59
3		60
4	IMPORTANT NOTE: Please mark your corrections and answers to these queries directly onto the	61
5	proof at the relevant place. Do NOT mark your corrections on this query sheet.	62
6		63
7	Queries from the Copyeditor:	64
8	AQ1 Is this entry correct?	65
9	AQ2 Please check rekeyed equation.	66
10	AQ3 OK?	67
11	AQ4 'other than'?	68
12		69
13		70
14		71
15		72
16		73
17		74
18		75
19		76
20		77
21		78
22		79
23		80
24		81
25		82
26		83
27		84
28		85
29		86
30		87
31		88
32		89
33		90
34		91
35		92
36		93
37		94
38		95
39		96
40		97
41		98
42		99
43		100
44		101
45		102
46		103
47		104
48		105
49		106
50		107
51		108
52		109
53		110
54		111
55		112
56		113
57		114

WILEY AUTHOR DISCOUNT CARD

As a highly valued contributor to Wiley's publications, we would like to show our appreciation to you by offering a **unique 25% discount** off the published price of any of our books*.

To take advantage of this offer, all you need to do is apply for the **Wiley Author Discount Card** by completing the attached form and returning it to us at the following address:

The Database Group
John Wiley & Sons Ltd
The Atrium
Southern Gate
Chichester
West Sussex PO19 8SQ
UK

In the meantime, whenever you order books direct from us, simply quote promotional code **S001W** to take advantage of the 25% discount.

The newest and quickest way to order your books from us is via our new European website at:

<http://www.wiley europe.com>

Key benefits to using the site and ordering online include:

- Real-time SECURE on-line ordering
- The most up-to-date search functionality to make browsing the catalogue easier
- Dedicated Author resource centre
- E-mail a friend
- Easy to use navigation
- Regular special offers
- Sign up for subject orientated e-mail alerts

So take advantage of this great offer, return your completed form today to receive your discount card.

Yours sincerely,



Verity Leaver
E-marketing and Database Manager

*TERMS AND CONDITIONS

This offer is exclusive to Wiley Authors, Editors, Contributors and Editorial Board Members in acquiring books (excluding encyclopaedias and major reference works) for their personal use. There must be no resale through any channel. The offer is subject to stock availability and cannot be applied retrospectively. This entitlement cannot be used in conjunction with any other special offer. Wiley reserves the right to amend the terms of the offer at any time.

REGISTRATION FORM FOR 25% BOOK DISCOUNT CARD

To enjoy your special discount, tell us your areas of interest and you will receive relevant catalogues or leaflets from which to select your books. Please indicate your specific subject areas below.

<p>Accounting <input type="checkbox"/></p> <ul style="list-style-type: none"> • Public <input type="checkbox"/> • Corporate <input type="checkbox"/> <p>Chemistry <input type="checkbox"/></p> <ul style="list-style-type: none"> • Analytical <input type="checkbox"/> • Industrial/Safety <input type="checkbox"/> • Organic <input type="checkbox"/> • Inorganic <input type="checkbox"/> • Polymer <input type="checkbox"/> • Spectroscopy <input type="checkbox"/> <p>Encyclopedia/Reference <input type="checkbox"/></p> <ul style="list-style-type: none"> • Business/Finance <input type="checkbox"/> • Life Sciences <input type="checkbox"/> • Medical Sciences <input type="checkbox"/> • Physical Sciences <input type="checkbox"/> • Technology <input type="checkbox"/> <p>Earth & Environmental Science <input type="checkbox"/></p> <p>Hospitality <input type="checkbox"/></p> <p>Genetics <input type="checkbox"/></p> <ul style="list-style-type: none"> • Bioinformatics/Computational Biology <input type="checkbox"/> • Proteomics <input type="checkbox"/> • Genomics <input type="checkbox"/> • Gene Mapping <input type="checkbox"/> • Clinical Genetics <input type="checkbox"/> <p>Medical Science <input type="checkbox"/></p> <ul style="list-style-type: none"> • Cardiovascular <input type="checkbox"/> • Diabetes <input type="checkbox"/> • Endocrinology <input type="checkbox"/> • Imaging <input type="checkbox"/> • Obstetrics/Gynaecology <input type="checkbox"/> • Oncology <input type="checkbox"/> • Pharmacology <input type="checkbox"/> • Psychiatry <input type="checkbox"/> <p>Non-Profit <input type="checkbox"/></p>	<p>Architecture <input type="checkbox"/></p> <p>Business/Management <input type="checkbox"/></p> <p>Computer Science <input type="checkbox"/></p> <ul style="list-style-type: none"> • Database/Data Warehouse <input type="checkbox"/> • Internet Business <input type="checkbox"/> • Networking <input type="checkbox"/> • Programming/Software Development <input type="checkbox"/> • Object Technology <input type="checkbox"/> <p>Engineering <input type="checkbox"/></p> <ul style="list-style-type: none"> • Civil <input type="checkbox"/> • Communications Technology <input type="checkbox"/> • Electronic <input type="checkbox"/> • Environmental <input type="checkbox"/> • Industrial <input type="checkbox"/> • Mechanical <input type="checkbox"/> <p>Finance/Investing <input type="checkbox"/></p> <ul style="list-style-type: none"> • Economics <input type="checkbox"/> • Institutional <input type="checkbox"/> • Personal Finance <input type="checkbox"/> <p>Life Science <input type="checkbox"/></p> <p>Landscape Architecture <input type="checkbox"/></p> <p>Mathematics/Statistics <input type="checkbox"/></p> <p>Manufacturing <input type="checkbox"/></p> <p>Material Science <input type="checkbox"/></p> <p>Psychology <input type="checkbox"/></p> <ul style="list-style-type: none"> • Clinical <input type="checkbox"/> • Forensic <input type="checkbox"/> • Social & Personality <input type="checkbox"/> • Health & Sport <input type="checkbox"/> • Cognitive <input type="checkbox"/> • Organizational <input type="checkbox"/> • Developmental and Special Ed <input type="checkbox"/> • Child Welfare <input type="checkbox"/> • Self-Help <input type="checkbox"/> <p>Physics/Physical Science <input type="checkbox"/></p>
--	---

I confirm that I am a Wiley Author/Editor/Contributor/Editorial Board Member of the following publications:

SIGNATURE:

PLEASE COMPLETE THE FOLLOWING DETAILS IN BLOCK CAPITALS:

TITLE AND NAME: (e.g. Mr, Mrs, Dr)

JOB TITLE:

DEPARTMENT:

COMPANY/INSTITUTION:

ADDRESS:

.....

.....

.....

TOWN/CITY:

COUNTY/STATE:

COUNTRY:

POSTCODE/ZIP CODE:

DAYTIME TEL:

FAX:

E-MAIL:

YOUR PERSONAL DATA

We, John Wiley & Sons Ltd, will use the information you have provided to fulfil your request. In addition, we would like to:

1. Use your information to keep you informed by post, e-mail or telephone of titles and offers of interest to you and available from us or other Wiley Group companies worldwide, and may supply your details to members of the Wiley Group for this purpose.
 Please tick the box if you do not wish to receive this information
2. Share your information with other carefully selected companies so that they may contact you by post, fax or e-mail with details of titles and offers that may be of interest to you.
 Please tick the box if you do not wish to receive this information.

If, at any time, you wish to stop receiving information, please contact the Database Group (databasegroup@wiley.co.uk) at John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, UK.

E-MAIL ALERTING SERVICE

We offer an information service on our product ranges via e-mail. If you do not wish to receive information and offers from John Wiley companies worldwide via e-mail, please tick the box .

This offer is exclusive to Wiley Authors, Editors, Contributors and Editorial Board Members in acquiring books (excluding encyclopaedias and major reference works) for their personal use. There should be no resale through any channel. The offer is subject to stock availability and may not be applied retrospectively. This entitlement cannot be used in conjunction with any other special offer. Wiley reserves the right to vary the terms of the offer at any time.

Ref: S001W